STOCKWATCH: Name, Platform; Time of death, December 2013
This article was originally published in Scrip
They only come out towards the end of an IPO window. After investors have snapped up all the preclinical or Phase I-stage drug development companies and the venture capitalists are scratching around their portfolios to off-load risk and negative cash flows onto the public markets from investments that weren't formed five minutes ago, then we see the platform companies.
You may also be interested in...
Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.
A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.
The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.